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ABSTRACT 
The water channel aquaporin-1 (AQP1) is the molecular counterpart of the ultrasmall pore 
that mediates free-water transport during peritoneal dialysis. Proof-of-principle studies 
performed in rats have shown that treatment with corticosteroids upregulates the expression of 
AQP1 in the peritoneal capillaries, causing a significant increase in free-water transport. 
Whether such a beneficial effect could be observed in end-stage renal disease patients treated 
by peritoneal dialysis remains unknown. Peritoneal transport parameters were evaluated in 
three patients on peritoneal dialysis, shortly before and after living-donor renal transplantation 
and treatment with high-dose methylprednisolone (1.0 to 1.2 gr/m2). As compared with pre-
transplantation values, the post-transplantation test revealed a ~2-fold increase in the sodium 
sieving and ultrasmall pore ultrafiltration volume, suggesting an effect on AQP1 water 
channels. In contrast, there was no change in the parameters of small solute transport. The 
direct involvement of AQP1 in these changes is suggested by the expression of glucocorticoid 
receptors in the human peritoneum and the presence of conserved glucocorticoid response 
elements in the promoter of the human AQP1 gene.  
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The capacity for ultrafiltration (UF) across the peritoneal membrane is a major 
predictor of outcome and mortality for end-stage renal disease patients treated with peritoneal 
dialysis (PD) (1,2). The major barrier for the transport of water and solutes across the 
peritoneal membrane is the endothelium lining peritoneal capillaries. Modeling of peritoneal 
transport has predicted that endothelial cells contain ultrasmall pores (radius < 3Å) that 
facilitate the osmotic transport of water during a hypertonic dwell (3). The ultrasmall pores 
account for half of the UF and their patency explains the “sodium sieving”, i.e. the marked 
fall of the dialysate to plasma ratio of sodium during the first hour of PD (3). Several lines of 
evidence have demonstrated that the water channel aquaporin-1 (AQP1), which is abundantly 
expressed in the endothelial cells lining peritoneal capillaries and veinules (4), is the 
molecular counterpart of the ultrasmall pores (5, for review). Studies in Aqp1-null mice 
demonstrated that AQP1 facilitates water transport and mediates approximately half of the UF 
during crystalloid osmosis (6,7). Accordingly, increasing the expression of AQP1 in the 
peritoneum could improve water transport in PD patients. Based on the presence of 
glucocorticoid response elements (GREs) in the promoter of the murine AQP1 gene (8), 
Stoenoiu et al. demonstrated that treatment with corticosteroids increases the expression of 
AQP1 in the peritoneal capillaries, mirrored by increased water transport and UF, without 
affecting the transport of small solutes (9). Thus far, it is unknown whether a similar effect 
could be evidenced in patients undergoing PD. We report the serial determination of water 
and solute transport parameters across the peritoneal membrane in three PD patients that 
received high-dose glucocorticoids as standard care after a living-donor renal transplantation. 
 
 
 
 
Page 3 of 15 Nephrology Dialysis Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
PATIENTS AND METHODS 
 The clinical features of the three PD patients are detailed in Table 1. Patient 1 is a 11 
year-old girl who presented hemolytic uremic syndrome at 18 months of age, progressing to 
ESRD at age 10. She was initially treated by CAPD for 6 months, followed by APD for 4 
months. Patient 2 is a 54 year-old male with autosomal dominant polycystic kidney disease 
(ADPKD) progressing to ESRD at age 52. He was treated by CAPD for 9 months before 
transplantation. Patient 3 is a 6 year-old boy who reached ESRD at age 5 for congenital 
vesico-ureteral reflux. He was treated by CAPD for 5 months. The course of PD was 
uncomplicated in the three patients. They underwent a living-donor renal transplantation after 
a mean of 8 months of PD (range: 5 to 10 months). The renal transplantation was uneventful, 
with immediate graft function in the three cases. The detail of cumulative methylprednisolone 
dose and immunosuppressive treatment is given in Table 1. The peritoneal function was 
assessed in the three patients using the Mini-Peritoneal Equilibration Testing (Mini-PET) (10) 
performed before (range: 1 day to 3 months) and after (range: 7 to 39 days) renal 
transplantation. The sodium concentration was measured by indirect ion selective analysis 
(Modular Analytics Evo 900, calibrated by ISE compensator; Roche Diagnostics, Buenos 
Aires, Argentina). The study was approved by the Ethical Review Board and informed 
consent was obtained.  
 The expression of the glucocorticoid receptor (GR) mRNA was assessed in human 
peritoneal biopsies using reverse transcription polymerase chain reaction (RT-PCR) (9). Total 
RNA was extracted from two human peritoneal biopsies (obtained a time of catheter removal 
in PD patients, Ref. 4) using Aurum TM Total RNA Tissue Kit (Bio-Rad, Hercules, CA), 
following the manufacturer’s protocol, followed by DNAse I treatment to eliminate genomic 
DNA contamination. Total RNA was extracted from human erythroleukemia (HEL) cells 
(positive control for GR expression) using RNAqueousR-Micro kit (Ambion). One microgram 
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of RNA was used to perform the reverse transcriptase reaction with iScript TM cDNA 
Synthesis Kit (Bio-Rad). RT-PCR detection was performed with FastStart Taq DNA 
Polymerase (Roche) for 32 cycles, and PCR products visualized on a 1.5% agarose gel with 
GelRed dye (Sigma). The primers were designed using Beacon Design 2.0 (Premier Biosoft 
International, Palo Alto, CA) : GAPDH (forward 5’-3’ : GGG GCT CTC CAG AAC ATC 
AT; and reverse 5’-3’: TCT AGA CGG CAG GTC AGG T) and GR (forward 5'-3':  ACA 
CTG CCC CAA GTG AAA AC; and reverse 5'-3': CCA TGA ACA GAA ATG GCA GA). 
 Immunostaining was performed on paraffin-embedded sections of human peritoneal 
biopsies by using a sequential staining protocol (4). Sections were incubated with 3% serum 
for 20 min before adding anti-von Willebrand factor (α-vWF, DAKO, Denmark) diluted in 
phosphate-buffered saline (PBS) containing 2% BSA for 1h. After washing, sections were 
incubated with Alexa633-labelled secondary anti-IgG antibodies (Invitrogen, Belgium) for 45 
min. The secondary staining was performed by adding anti-glucocorticoid receptor (α-GR, 
Abcam, Belgium) and labelled with Alexa488-labelled secondary anti-IgG antibodies before 
mounting in Prolong Gold Anti-fade reagent (Invitrogen, Belgium). Sections were viewed 
under a Zeiss LSM510Meta Confocal microscope (Zeiss, Belgium), using x20 Plan-
Apochromat or x63/1.4 Plan-Apochromat oil-immersion objectives (Zeiss).  
 The 3kb promoter sequence of the human AQP1 gene was analyzed for putative GRE 
using Transcription Element Search Software (TESS; http://www.cbil.upenn.edu/cgi-
bin/tess/tess). 
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RESULTS AND DISCUSSION 
 The evolution of the peritoneal transport parameters as assessed by the Mini-PET is 
shown on Table 1. As compared with pre-transplantation, the post-transplantation PET 
evidenced an approximately 2-fold increase in the sodium sieving (and its surrogate marker 
the absolute dip of dialysate sodium concentration) (11), paralleled by a similar increase in the 
ultrasmall pore-specific UF. In contrast, the small solute transport rate, as assessed by the D/P 
creatinine and small pore-specific UF was unchanged (Fig. 1A, Table 1). By analogy with 
results obtained in the rat (9), the potential role of AQP1 was substantiated by expression 
studies demonstrating the expression of the GR in the capillary endothelium of the human 
peritoneum, and the in silico identification of conserved GREs in the promoter of the AQP1 
gene (Fig. 1B-D). 
 These data are the first to document a major increase in the parameters of free-water 
transport in PD patients following high-dose glucocorticoid administration in the context of 
renal transplantation. To the best of our knowledge, there are no previous reports on the effect 
of renal transplantation per se on PD transport parameters. Several points argue in favour of a 
specific effect of the glucocorticoids on AQP1. First, the time-course of the effect, similarly 
observed in the three patients who had all a short course of uncomplicated PD followed by a 
living-donor renal transplantation with immediate renal function. Second, the fact that the 
changes are restricted to the very parameters – sodium sieving, sodium dip and ultrasmall 
pore-specific UF – that reflect the AQP1-mediated water transport, whereas there is no effect 
on the D/P creatinine parameter assessing small solute transport. The lack of effect of small 
solutes is important when considering that exposure to mycophenolate mofetil (MMF) can, at 
least in vitro, inhibit angiogenesis (12,13) and thus decrease the exchange area. Third, the fact 
that no other external factor other than high-dose glucocorticoids has been reported to 
specifically affect free-water transport and expression of AQP1. Fourth, we provide evidence 
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for multiple GREs in the promoter of the AQP1 gene and for a strong expression of the GR in 
the endothelium lining peritoneal capillaries, i.e. in the very cells where AQP1 mediates 
osmotic water transport during PD. We fully acknowledge the limitations of this preliminary 
report, including the small number of patients, with only one adult, not very representative of 
the PD population, and the lack of low-dose steroid controls assessing the effect of 
transplantation (e.g. removing uremia, inducing acute changes in body parameters, and 
putting the peritoneal membrane at rest). These limitations are balanced by the specificity of 
the changes in free-water transport and the lack of effect on other transport parameters (Figure 
1). We should also keep in mind the possibility of a role for the interstitium in the water-only 
fluid pathway (14), although the time-course for a dramatic reorganization of the interstitium 
(except for a reduction in the degree of oedema) seems to be too short for such an explanation 
of the observed changes.  
 In conclusion, these data provide the first line of evidence supporting the effect of 
corticosteroids on specific parameters of AQP1-mediated water transport in PD patients. 
Although these results have to be confirmed on a larger patient material, the specificity of the 
changes in free-water transport suggests that pharmacologic induction of AQP1 may help to 
increase water transport in patients treated by PD.  
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FIGURE LEGEND 
 
Figure 1. Transport parameters before and after renal transplantation and expression of the 
glucocorticoid receptor (GR) in the human peritoneum. 
A. Comparison of the transport parameters before and after renal transplantation. 
A mini-PET was performed before and after transplantation in the three patients, who 
received methylprednisolone (1 g/m2) at time of transplantation. As compared with baseline 
values, the three patients show a ∼ 2-fold increase in the sodium sieving and in the ultrasmall-
pore specific (USP) ultrafiltration (mL) post-transplantation, whereas the transport of small 
solutes (D/P creatinine) remains unchanged. Individual values are given in Table 1. 
B. Reverse transcription polymerase chain reaction (RT-PCR) demonstrating the expression 
of the GR (153 bp) in two peritoneal biopsies from patients on peritoneal dialysis and in the 
control human erythroleukemia (HEL) cells. 
C. Immunolocalization of the GR in human peritoneum. Double immunostaining with anti-
glucocorticoid receptor (α-GR) and anti-von Willebrand factor (α-vWF) antibodies show that 
the GR is expressed in endothelial cells  lining capillaries and small vessels in the peritoneal 
membrane. Low magnification: bar: 50µm; detail: 10µm. m, mesothelium. 
D. Organization of human aquaporin-1 (AQP1) gene promoter. The 3-kilobase (kb) proximal 
promoter of AQP1 is schematically represented, including the transcription start site and the 
16 predicted glucocorticoid response elements (GRE, vertical symbols). 
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Table 1 R1: Clinical and peritoneal equilibration test (Mini-PET) parameters in the three patients. 
 Patient 1 Patient 2 Patient 3 
Gender, age (years) Female, 11  Male, 54  Male, 6  
Cause of ESRD Hemolytic uremic syndrome ADPKD Congenital reflux 
Age at ESRD (years) 10 52 5 
Duration of PD (months), modality 10, CAPD (6) then APD (4) 9, CAPD 5, CAPD 
Residual diuresis on PD (mL per day) 500  1000 500 
Time of pre-transplant mini-PET (days) 1 day 90 days  2 days 
Methylprednisolone dose (gr per m2)a 1.0 1.0 1.2 
Other (immunosuppressive) drugs 
introduced per-transplantation 
Daclizumab (1mg/kg) 
Tacrolimus) (0.15 mg/kg/day) 
MMF 1 gr/day 
Tacrolimus: 0.15 mg/kg/day 
MMF: 2 gr/day 
 
Daclizumab (1mg/kg) 
Tacrolimus: (0.15 mg/kg/day) 
MMF: 1 gr/day 
Time to post-transplant Mini-PET (days) 7 20 39 
Serum creatinine at posttransplant  Mini-
PET (mg/dL) 
0.44 1.2 0.43 
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Table 1 R1 (cont.) 
 Patient 1 Patient 2 Patient 3 
 Pre-TP Post-TP Pre-TP Post-TP Pre-TP Post-TP 
Sodium sieving (%)b 8.3 11.4 5.4 13.1 4.4 12.7 
Sodium dip (mmol/L)c 11 15 7 17 6 17 
Ultrafiltration USP (mL) 126 150 170 332 30 90 
Ultrafiltration 1h (mL) 240 180 620 380 60 180 
D/P creatinine 0.40 0.47 0.54 0.46 0.66 0.66 
Volume infused (L/m2) 1.1 1.1 1.2 1.2 0.9 0.9 
 
ADPKD, autosomal dominant polycystic kidney disease; APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; 
ESRD, end-stage renal disease; MMF, mycophenolate mofetil; PD, peritoneal dialysis; PET, peritoneal equilibration test. 
a
, cumulative dose until post-transplantation Mini-PET; b, sodium sieving: (D0/P0 – D60/P60)/D0/P0 x 100 (in %) (Ref. 7); c, sodium dip: absolute dip 
of dialysate sodium concentration at 60 min of the PET (mmol/L) (11). 
D/P, dialysate-over-plasma ratio; Post-TP, post-transplantation; Pre-TP, pre-transplantation; USP, ultrasmall pores 
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